Moreover, at a molecular level, MM has been proven to be different from its cutaneous counterpart such as a higher rate of KIT aberrations (mutations or copy number increase) and a less frequency of BRAF mutations.[12] These could be the explanations for the relatively poor survival outcomes of MM compared with OM. The gene discussed is BRAF; the disease is Miyoshi myopathy.